Protective agent for retinal nerve or optic nerve
- Summary
- The present invention provides a protective agent for retinal nerve or optic nerve which exerts its effect through a different mechanism from that of conventional therapeutic agents and can be taken for long periods. The present invention is the protective agent for retinal nerve or optic nerve which comprises a compound with aldose reductase inhibiting activity such as the compound represented by the following general formula as an active ingredient. A preferable compound thereof is (2S,4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide: wherein X represents a halogen atom or a hydrogen atom, R1 and R2 independently represent a hydrogen atom or an optionally substituted C1 to C6 alkyl group, or R 1 and R 2 , together with a nitrogen atom bound thereto, or optionally another nitrogen atom or an oxygen atom, are combined to form a 5- to 6-membered heterocycle.
- Supplementary Information
- Patent Number: US8536212B2
Application Number: US2009517882A
Inventor: Chung, Sookja Kim | Chung, Stephen | Hibi, Chihiro
Priority Date: 31 Jan 2007
Priority Number: US8536212B2
Application Date: 17 Mar 2010
Publication Date: 17 Sep 2013
IPC Current: A01N004350
US Class: 514389
Assignee Applicant: Sanwa Kagaku Kenkyusho Co. Ltd.
Title: Protective agent for retinal nerve or optic nerve
Usefulness: Protective agent for retinal nerve or optic nerve
Summary: The agent is useful for protecting retina nerve or optic nerve, for treating fall of visual performance or deterioration resulting from retinal ischemia or retinal ischemia reperfusion injury in glaucoma, maculopathy, uveitis, or ocular blood vessel obstruction, where the retinal ischemia reperfusion injury includes age-related macular degeneration, diabetic maculopathy, diabetic retinopathy, photocoagulation with respect to BRVO (branch retinal vein occlusion) or CRVO (central retinal vein occlusion), vitreous surgery, or medical treatment with respect to primary open-angle glaucoma or normal tension glaucoma, or laser trabeculoplasty, primary closure angle glaucoma, laser iridotomy, surgical iridectomy, or the condition which occurs after thrombolytic therapy with respect to intractable optic neuropathy (all claimed).
Novelty: Agent for protecting retina nerve or optic nerve, comprises compound having aldose reductase inhibitory effect
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Other Disease
- Application No.
- CN200880003451A
- Country/Region
- Hong Kong
For more information, please click Here
